McGill University Health Centre Research InstituteMontreal, Quebec, Canada
Disclosure information not submitted.
Paper 106 - SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Saturday, November 16, 20243:30 PM – 4:30 PM PST